'New' Biohaven up 81% days after Pfizer acquisition as investors see pipeline potential

Retrieved on: 2022-10-06 17:42:45

Tags for this article:

Neurological disorders

Health

Organ systems

Rare diseases

Autosomal dominant disorders

Pfizer

Spinocerebellar ataxia

Ataxia

Biohaven Ltd.

Biohaven Pharmaceuticals

Click the tags to see associated articles and topics

'New' Biohaven up 81% days after Pfizer acquisition as investors see pipeline potential. View article details on HISWAI: https://seekingalpha.com/news/3889416-new-biohaven-up-81-days-after-pfizer-acquisition-as-investors-see-pipeline-potential%3Fsource%3Dcontent_type%253Areact%257Cfirst_level_url%253Amarket-news%257Csection_asset%253Amain%257Csection%253Aon-the-move

Excerpt

Although Pfizer completed its acquisition of Biohaven Pharmaceutical, the company lives on as a separately traded company, Biohaven Ltd., ...

Article found on: seekingalpha.com

View Original Article